CVRx, Inc. (NASDAQ:CVRX) Receives Average Rating of "Moderate Buy" from Brokerages

Shares of CVRx, Inc. (NASDAQ:CVRX - Get Free Report) have received an average rating of "Moderate Buy" from the seven analysts that are presently covering the stock, Marketbeat.com reports. Two research analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $15.83.

Several research analysts recently commented on CVRX shares. Cantor Fitzgerald reiterated an "overweight" rating and issued a $14.00 price target on shares of CVRx in a research report on Wednesday, October 23rd. Canaccord Genuity Group increased their price target on CVRx from $15.00 to $17.00 and gave the company a "buy" rating in a report on Wednesday, October 30th. Lake Street Capital lifted their price objective on shares of CVRx from $12.00 to $15.00 and gave the stock a "buy" rating in a research note on Wednesday, October 30th. Piper Sandler reaffirmed an "overweight" rating and set a $16.00 target price (up previously from $13.00) on shares of CVRx in a research note on Wednesday, October 30th. Finally, Craig Hallum lifted their target price on CVRx from $15.00 to $20.00 and gave the stock a "buy" rating in a research report on Monday, November 4th.

Institutional Investors Weigh In On CVRx

Several institutional investors have recently bought and sold shares of the company. SG Americas Securities LLC purchased a new stake in shares of CVRx during the 3rd quarter valued at $108,000. XTX Topco Ltd acquired a new stake in CVRx in the third quarter worth about $150,000. Jane Street Group LLC increased its holdings in shares of CVRx by 36.1% during the third quarter. Jane Street Group LLC now owns 19,038 shares of the company's stock valued at $168,000 after acquiring an additional 5,053 shares in the last quarter. Barclays PLC boosted its stake in CVRx by 312.5% in the 3rd quarter. Barclays PLC now owns 19,067 shares of the company's stock worth $169,000 after purchasing an additional 14,445 shares in the last quarter. Finally, Centiva Capital LP purchased a new stake in CVRx during the 3rd quarter worth approximately $178,000. 75.27% of the stock is currently owned by institutional investors and hedge funds.

CVRx Stock Performance

Shares of CVRX stock traded down $0.22 during trading hours on Friday, hitting $13.91. The stock had a trading volume of 155,194 shares, compared to its average volume of 507,755. The company has a current ratio of 11.32, a quick ratio of 10.23 and a debt-to-equity ratio of 0.76. CVRx has a one year low of $6.40 and a one year high of $33.13. The stock's 50-day moving average price is $10.29 and its two-hundred day moving average price is $9.55.

CVRx (NASDAQ:CVRX - Get Free Report) last issued its quarterly earnings data on Tuesday, October 29th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.45) by ($0.12). CVRx had a negative return on equity of 89.06% and a negative net margin of 123.75%. The firm had revenue of $13.37 million for the quarter, compared to analysts' expectations of $13.28 million. During the same period last year, the company earned ($0.43) earnings per share. As a group, research analysts anticipate that CVRx will post -2.62 EPS for the current year.

About CVRx

CVRx, Inc, a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure.